Profile data is unavailable for this security.
About the company
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
- Revenue in USD (TTM)0.00
- Net income in USD-102.06m
- Incorporated2017
- Employees58.00
- LocationPassage Bio IncOne Commerce Square2005 Market Street, 39Th FloorPHILADELPHIA 19103United StatesUSA
- Phone+1 (267) 866-0312
- Fax+1 (302) 655-5049
- Websitehttps://www.passagebio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Provectus Biopharmaceuticals Inc | 557.71k | -3.10m | 80.25m | 4.00 | -- | -- | -- | 143.90 | -0.0074 | -0.0074 | 0.0013 | -0.0181 | 0.32 | -- | 1,282.09 | 139,427.50 | -177.95 | -276.33 | -- | -- | -- | -- | -556.16 | -1,667.76 | -- | -13.22 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Aileron Therapeutics Inc | 0.00 | -15.73m | 80.76m | 15.00 | -- | 2.71 | -- | -- | -3.39 | -3.39 | 0.00 | 20.12 | 0.00 | -- | -- | 0.00 | -24.58 | -65.99 | -26.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -10.49m | 80.91m | 2.00 | -- | 12.47 | -- | -- | -0.4087 | -0.4087 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -86.04 | -- | -95.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Jaguar Health Inc | 9.76m | -41.30m | 80.99m | 49.00 | -- | 4.34 | -- | 8.30 | -3.64 | -3.64 | 0.4239 | 0.0676 | 0.1988 | 0.2513 | 5.08 | 199,204.10 | -85.33 | -95.29 | -153.34 | -163.54 | 79.13 | 67.28 | -429.27 | -522.28 | 1.34 | -2.95 | 0.8799 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| MDxHealth SA - ADR | -100.00bn | -100.00bn | 81.05m | 258.00 | -- | 11.24 | -- | -- | -- | -- | -- | 0.2641 | -- | -- | -- | -- | -- | -51.62 | -- | -64.72 | -- | 50.90 | -- | -117.64 | 1.81 | -- | 0.8513 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| LAVA Therapeutics NV | 6.77m | -41.97m | 81.50m | 37.00 | -- | 1.59 | -- | 12.04 | -1.58 | -1.58 | 0.2532 | 1.95 | 0.0552 | -- | 2.87 | 182,946.00 | -34.25 | -- | -40.31 | -- | 48.56 | -- | -620.09 | -- | -- | -- | 0.1098 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Personalis Inc | 73.48m | -108.30m | 81.94m | 223.00 | -- | 0.624 | -- | 1.12 | -2.25 | -2.25 | 1.53 | 2.56 | 0.2838 | 5.80 | 4.28 | 329,511.20 | -41.83 | -28.84 | -49.51 | -34.72 | 24.78 | 28.65 | -147.38 | -96.01 | 2.89 | -- | 0.0218 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| Passage Bio Inc | 0.00 | -102.06m | 82.56m | 58.00 | -- | 0.6616 | -- | -- | -1.87 | -1.87 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -51.80 | -48.56 | -56.80 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Beyondspring Inc | 1.75m | -21.03m | 84.08m | 35.00 | -- | -- | -- | 48.02 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -7.45m | 84.45m | 12.00 | -- | 4.95 | -- | -- | -0.5863 | -0.5863 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -82.73 | -- | -113.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Chimerix Inc | 41.00k | -82.59m | 84.77m | 72.00 | -- | 0.4892 | -- | 2,067.50 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -27.03m | 84.84m | 28.00 | -- | 2.19 | -- | -- | -0.5642 | -0.5642 | 0.00 | 0.7889 | 0.00 | -- | -- | 0.00 | -47.51 | -38.31 | -56.21 | -43.34 | -- | -- | -- | -- | -- | -6.33 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Lynx1 Capital Management LPas of 19 Mar 2024 | 4.85m | 8.72% |
| Tang Capital Management LLCas of 31 Dec 2023 | 2.40m | 4.32% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.01m | 3.61% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.22m | 2.20% |
| Millennium Management LLCas of 31 Dec 2023 | 788.18k | 1.42% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 732.10k | 1.32% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 604.68k | 1.09% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 506.60k | 0.91% |
| Acuitas Investments LLCas of 31 Dec 2023 | 417.73k | 0.75% |
| Geode Capital Management LLCas of 31 Dec 2023 | 332.20k | 0.60% |
